ERBB2 and breast cancer: The development of these approaches in the context of BC is opening the way to translate soon the acquired expertise to CTCs biomarkers analysis, obtaining more sensitive and reproducible tools for a refined HER2 quantification on CTCs, overcoming the categorization of CTCs into 0, 1+, 2+, 3+, for a continuous score of HER2 expression.